What is ExoCoBio?
ExoCoBio operates at the intersection of biotechnology and aesthetic medicine, specializing in the development and manufacturing of exosome-based products. By leveraging the regenerative properties of exosomes, the company provides advanced solutions for skin rejuvenation and therapeutic applications. As a leader in the Korean biotech ecosystem, ExoCoBio maintains a rigorous focus on clinical validation and high-quality manufacturing standards, effectively bridging the gap between laboratory research and commercial-grade aesthetic products. Its market position is bolstered by a robust intellectual property portfolio and a clear strategic vision for the future of regenerative aesthetics.
How much funding has ExoCoBio raised?
ExoCoBio has raised a total of $47M across 3 funding rounds:
Series A
$11M
Series B
$26.7M
Series C
$9.3M
Series A (2017): $11M, investors not publicly disclosed
Series B (2018): $26.7M led by KDB Capital, SEVEN TREE EQUITY PARTNERS, K2 Investment, Atinum Investment Co., Intervest International Equities, and TS Partners
Series C (2020): $9.3M supported by K2 Investment Group, Focus Asset Management, G.N. Tech/ReeHu Investment, SBI Investment Korea Co., Ltd., and DT Investment Partners LLC
Key Investors in ExoCoBio
KDB Capital
A prominent South Korean financial institution providing comprehensive investment services and venture capital support to high-growth technology firms.
Atinum Investment Co.
A leading venture capital firm in Korea known for its strategic focus on early-to-growth stage companies within the technology and healthcare sectors.
SBI Investment Korea Co., Ltd.
A major investment arm of the SBI Group, specializing in providing growth capital to innovative startups across various high-tech industries.
What's next for ExoCoBio?
With the successful closure of its latest financing round, ExoCoBio is well-positioned to transition into a phase of aggressive market expansion and product diversification. The company is expected to utilize these resources to enhance its R&D pipeline, potentially exploring new therapeutic indications for its exosome technology beyond the aesthetic domain. Furthermore, the strategic backing from institutional investors provides the necessary operational leverage to navigate complex regulatory landscapes in international markets. As the firm continues to scale, the focus will likely shift toward optimizing supply chain efficiencies and strengthening its global distribution network to meet the rising demand for innovative, science-backed dermatological treatments.
See full ExoCoBio company page
